Lexeo Therapeutics, Inc. (LXEO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.89+1.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LXEO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenues | — | — | — | — | 0.7 | — |
| Operating Expenses & Income | ||||||
| R&D Expenses | 66.6 | 63.8 | 74.1 | 53.1 | 49.2 | — |
| Operating Income | (95.1) | (109.3) | (105.8) | (68.5) | (60.5) | — |
| Earnings from Continuing Operations | ||||||
| Interest Expense | — | 0.1 | 0.1 | 0.2 | 0.1 | — |
| Interest & Investment Income | 8.0 | 6.1 | 7.6 | 2.9 | 1.3 | — |
| Net Interest Expenses | — | — | — | (2.7) | (1.2) | — |
| Other Non-Operating Income / Expenses | 7.9 | 9.3 | 7.4 | 2.1 | 1.2 | — |
| EBT, Incl. Unusual Items | (87.0) | (99.7) | (98.3) | (66.4) | (59.3) | — |
| Net Income | ||||||
| Net Income | (87.3) | (100.0) | (98.3) | (66.4) | (59.3) | — |
| Per Share | ||||||
| Basic EPS | (1.02) | (1.86) | (3.09) | (12.40) | (36.36) | — |
| Diluted EPS | (1.02) | (1.86) | (3.09) | (12.40) | (36.36) | — |
| Basic Weighted Avg Shares | 85.6 | 53.6 | 31.8 | 5.4 | 1.6 | — |
| Diluted Weighted Avg Shares | 85.6 | 53.6 | 31.8 | 5.4 | 1.6 | — |
| Supplemental | ||||||
| EBITDA | — | (109.0) | (105.5) | (68.2) | (60.4) | — |
| EBIT | (95.1) | (109.3) | (105.8) | (68.5) | (60.5) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.